SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-008767
Filing Date
2022-05-13
Accepted
2022-05-13 16:32:57
Documents
57
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrbo-20220331x10q.htm   iXBRL 10-Q 938554
2 EX-31.1 nrbo-20220331xex31d1.htm EX-31.1 17139
3 EX-32.1 nrbo-20220331xex32d1.htm EX-32.1 10966
  Complete submission text file 0001558370-22-008767.txt   4309324

Data Files

Seq Description Document Type Size
4 EX-101.SCH nrbo-20220331.xsd EX-101.SCH 37442
5 EX-101.CAL nrbo-20220331_cal.xml EX-101.CAL 31229
6 EX-101.DEF nrbo-20220331_def.xml EX-101.DEF 140159
7 EX-101.LAB nrbo-20220331_lab.xml EX-101.LAB 325539
8 EX-101.PRE nrbo-20220331_pre.xml EX-101.PRE 234503
51 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20220331x10q_htm.xml XML 677853
Mailing Address 200 BERKELEY ST. FL 19 BOSTON MA 02116
Business Address 200 BERKELEY ST. FL 19 BOSTON MA 02116 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 22923342
SIC: 2834 Pharmaceutical Preparations